MB Therapeutics raises 2 million euros
MB Therapeutics takes a new step in its development by raising €2 million in its first seed funding round.
This financing, supported by strategic investors such as Beprep, Calyseed, Angels Santé, “Banque Populaire d’Investissement” (BPI), as well as Business Angels specializing in pharmaceutical preparations like Sébastien Gallice, will enable the company to develop and launch the first industrial solution for 3D printing personalized medicines in pharmacies.
This new chapter strengthens MB Therapeutics’ position in the pharmaceutical market by introducing an innovative, turnkey solution for manufacturing personalized medicines in pharmacies.
Towards a New Era of Personalized Medicine
Today, standard treatments are increasingly tailored to the individual needs of patients. Thanks to 3D printing, MB Therapeutics is developing a technology that customizes drug dosages, shapes, and compositions to meet each person’s unique requirements. This approach enables more effective and better-tolerated treatments while reducing pharmaceutical waste.
With this funding round, MB Therapeutics has set several ambitious goals:
-
Strengthening research and development of its pharmaceutical 3D printing technology.
-
Optimizing production processes to scale up to an industrial level.
-
Structuring its teams and recruiting new talent to support growth.
-
stablishing strategic collaborations with laboratories, hospitals, and pharmaceutical industries.
An ambition for growth and leadership
With this funding round, MB Therapeutics strengthens its ambition to become a key player in the field of personalized medicine. The startup positions itself as the only provider of industrial-scale 3D printing solutions for pharmacies, a rapidly growing sector valued at $12 billion with an annual growth rate of 7%.
The funds will enable MB Therapeutics to launch its first pharmaceutical ink solutions for the production of personalized medicines in pharmacies by 2025, starting with three high-demand drugs. Additionally, the company is preparing for a future funding round in 2026 to support its international expansion and solidify its leadership in customized drug manufacturing.
MB Therapeutics, a magic project
Founded in 2023, MB Therapeutics is on a mission to develop innovative solutions for the pharmaceutical industry. The project was born from a simple observation: patients often face medications that are not well-suited to their needs, whether in dosage or release profile. With this in mind, Dr. Stéphane Roulon, an engineer, and Dr. Ian Soulairol, a hospital pharmacist at CHU de Nîmes, combined their expertise to create MB Therapeutics.
The company has developed a unique technology based on pharmaceutical inks, enabling the production of personalized medicines directly in pharmacies. This innovation paves the way for tailored treatments that better meet patients’ needs while ensuring both efficacy and safety.
With a strong focus on innovation and collaboration, MB Therapeutics surrounds itself with experts and strategic partners to accelerate the development and commercialization of its solutions. Supported by key funding, the company continues to grow, actively contributing to the evolution of the pharmaceutical sector by bringing tangible and scalable advancements.
A few words from the MB Therapeutics team:
This funding round gives us the means to go further and faster, positioning MB Therapeutics as a key player in the pharmacy of the future. We warmly thank our investors, partners, and teams who make this adventure possible. It is through this synergy that we can bring our vision to life and build a future where every patient receives treatment perfectly tailored to their needs. This is just the beginning of an exciting transformation.
